For patients with type 2 diabetes who are taking multiple daily insulin injections, switching to combination treatment with basal insulin plus an agent from one of two newer glucose-lowering drug ...

Hyperglycemia is a marker for poor clinical outcome and mortality in hospitalized patients. In the critical care setting, insulin administered intravenously or subcutaneously is effective.

Continuous subcutaneous insulin infusion (CSII) has become an indispensable modality in the management of type 1 diabetes. This therapy employs an insulin pump to deliver both basal and bolus doses, ...

You can manage type 2 diabetes several ways, including with a healthy diet and regular exercise. But sometimes, you may need insulin and other medication to help control your blood sugar levels. The ...

Diabetes, particularly type 2 diabetes (T2D), has become an epidemic in the United States, with a significant portion of patients unable to meet recommended glycemic targets. All individuals with type ...

COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in ...